Mineralys Therapeutics, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Mineralys Therapeutics, Inc. (Nasdaq: MLYS) is a clinical-stage biopharmaceutical company that develops medicines targeting hypertension and related comorbidities including chronic kidney disease, obstructive sleep apnea and other aldosterone-driven diseases. The company offers lorundrostat, a proprietary orally administered highly selective aldosterone synthase inhibitor designed to reduce aldosterone production by inhibiting the CYP11B2 enzyme, for the treatment of uncontrolled hypertension, resistant hypertension, chronic kidney disease in hypertensive patients and obstructive sleep apnea with hypertension; its clinical pipeline features completed Phase 3 Launch-HTN and Phase 2 Advance-HTN trials demonstrating robust systolic blood pressure reductions and favorable safety profiles in uncontrolled and resistant hypertension patients, Phase 2 Explore-CKD and Explore-OSA trials evaluating efficacy in kidney disease and sleep apnea comorbidities, and the ongoing Transform-HTN open-label extension trial gathering long-term safety and efficacy data. Founded in 2020 and headquartered in Radnor, Pennsylvania, Mineralys Therapeutics holds an exclusive license from Mitsubishi Tanabe Pharma for lorundrostat intellectual property and operates primarily in the United States with plans for global expansion through potential partnerships. In September 2025, the company completed a public equity financing raising gross proceeds of approximately $287.5 million to strengthen its balance sheet to $593.6 million in cash, cash equivalents and investments sufficient into 2028; it plans New Drug Application submission for lorundrostat to the FDA in late 2025 or first-quarter 2026 following positive pre-NDA feedback, completed enrollment in the Phase 2 Explore-OSA trial with topline results expected in first-quarter 2026, and reported a Q3 2025 net loss of $36.9 million amid reduced R&D expenses post-pivotal trial completion.
Company News
Mineralys: Why I'm Making Stock A Buy Ahead Of Hypertension Approval Decision
Canada Pension Plan Investment Board Buys New Holdings in Mineralys Therapeutics, Inc. $MLYS
BlackRock Inc. Buys New Position in Mineralys Therapeutics, Inc. $MLYS
Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript
Mineralys Therapeutics Q2 Earnings Call Highlights
Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
Mineralys Therapeutics, Inc. (MLYS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing
Mineralys' pill cuts blood pressure in kidney disease patients
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)